



GIG
CYMRU
NHS
WALES

Bwrdd Iechyd Prifysgol
Cwm Taf Morgannwg
University Health Board



Freedom of Information Request: Our Reference CTMUHB_38_25

You asked:

I am analysing the usage of intra-vitreous injections or implants by the NHS. I would greatly appreciate if you could answer the following questions:

1. How many of the following intra-vitreous injections/implants has your trust administered in the four-month period from September to December 2024:

- **Aflibercept**
- **Bevacizumab**
- **Brolucizumab**
- **Dexamethasone**
- **Faricimab**
- **Fluocinolone acetonide**
- **Ranibizumab – Lucentis**
- **Ranibizumab - Biosimilar (Ongavia, Ximluci, Byooviz, Rimmyrah)**

Please see the data provided below.

• Aflibercept	1374
• Bevacizumab	19
• Brolucizumab	0
• Dexamethasone	61
• Faricimab	1179
• Fluocinolone acetonide	**
• Ranibizumab – Lucentis	13
• Ranibizumab - Biosimilar (Ongavia, Ximluci, Byooviz, Rimmyrah)	0

Where the figures are less than 5, this has been denoted by **. The exact figures have been withheld due to the low numbers involved.

Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. The data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.

2. Please provide the number of injections/implants by eye condition for the four-month period from September to December 2024:

Number of Injections/Implants: September to December 2024:

Treatment	Eye Conditions		
	Wet Age-Related Macular Degeneration (wAMD)	Diabetic Macular Oedema (DMO)	Retinal Vein Occlusion (RVO)
Aflibercept	719	220	425
Bevacizumab	Not captured	Not captured	Not captured
Dexamethasone	0	**	6
Faricimab	801	361	17
Ranibizumab - Lucentis	5	**	0
Ranibizumab – Biosimilar (Ongavia, Ximluci, Byooviz, Rimmyrah)	0	0	0

Where the figures are less than 5, this has been denoted by **. The exact figures have been withheld due to the low numbers involved (please see response to Q1).